Solid Biosciences (SLDB) Cash from Operations (2017 - 2026)

Solid Biosciences has disclosed Cash from Operations across 10 years of filings, most recently posting 47230000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 47230000.0, down 48.29% year-over-year; the trailing twelve-month figure through Mar 2026 was 171669000.0 (down 60.93% YoY), and the FY2025 annual result was 156289000.0, down 56.27% from the prior year.
• Cash from Operations came in at 47230000.0 for Q1 2026 at Solid Biosciences, up from 53555000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 15878000.0 in Q2 2022 to a low of 53555000.0 in Q4 2025.
• The 5-year median for Cash from Operations is 27465000.0 (2023), against an average of 29158117.65.
• Across the five-year window, Cash from Operations surged 39.61% in 2023 and plunged 80.65% in 2025, its largest moves.
• Solid Biosciences' Cash from Operations stood at 34480000.0 in 2022, then soared by 39.61% to 20823000.0 in 2023, then tumbled by 42.37% to 29645000.0 in 2024, then plunged by 80.65% to 53555000.0 in 2025, then advanced by 11.81% to 47230000.0 in 2026.
• The last three Cash from Operations figures came in at 47230000.0 (Q1 2026), 53555000.0 (Q4 2025), and 33472000.0 (Q3 2025), per Business Quant data.